Eylea

Regeneron

Eylea's success makes Regeneron vulnerable to Medicare payment shift

If a proposed change in the way Medicare pays for injected drugs that doctors give at their offices goes forward, some companies will be hit harder than others. And according to a new report, one drugmaker in particular is at risk: Regeneron. And that is because of its strength in the marketplace, Eylea.